47. A compound of any of claims 1-41, or a pharmaceutically acceptable salt thereof, for use in the treatment of an inflammatory disease.

48. The use or compound of any of claims 1-41, or a pharmaceutically acceptable salt thereof, wherein the inflammatory disease is asthma.

49. A method of preventing, treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient, comprising administering to the patient a therapeutically effective amount of a compound of any of claims 1-41, or a pharmaceutically acceptable salt thereof.

50. The method of claim 49, wherein the disease or condition is asthma.

51. The method of claim 50, wherein the Janus kinase is JAK1.